Biopharma PEG Supplies PEG Products For Lipid Nanoparticles (LNPs)
Polyethylene glycol (PEG) is a polymer formed by condensation of ethylene oxide and water. As a kind of polymer material, PEG has good moisture, lubrication, biocompatibility, and non-toxic to human body, non-irritating, widely used in daily chemical, medicine, paint, food, pesticides, metals and other fields. In the field of medicine, PEG is mainly used to modify drugs (long-term, detoxification, etc.), modify medical instruments (hemostasis, adhesion, anti-leakage and anti-adhesion, etc.).
Since the first PEG modified drug was approved worldwide in 1990, more than 30 PEG modified drugs have been approved by the FDA or the European Union in the international market by the end of 2019. More than 2,000 projects are under development, and the market size exceeds $10 billion. Except for 2 small molecule drugs and 1 liposome drug, all the approved drugs are pegylated protein peptide drugs.
The PEGylated drug delivery platform is the frontier application of PEG in the pharmaceutical field. PEG modification technology can also be used in delivery systems such as siRNA, mRNA, and pDNA. The development of related technologies and drug research and development in the future will greatly drive the development of of pegylated drug delivery platform.
LNP (Lipid Nanoparticle) is the most mainstream non-viral vector for delivering mRNA. It is composed of ionizable lipids, which are positively charged at low pH and neutralize the negative charge of mRNA. In addition, LNPs include neutral lipids and cholesterol, which self-assemble into a core lipid structure with a surface layer that mimics a cell membrane. Finally, LNP incorporates phospholipids conjugated to PEG to increase the hydrophilicity of the LNP surface and provide stability to the mRNA carrier.
Currently, an important application of PEGylated delivery technology worldwide is the rapid development of mRNA COVID-19 vaccines based on PEGylated lipid nanoparticles. The three major mRNA vaccine giants, Moderna, CureVac and BioNTech, have all adopted the technology.
“The LNP technology has been adopted for COVID-19 vaccine manufacture. Biopharma PEG supplies mPEG-DSPE, mPEG-DMG, mPEG-OH, mPEG-N,N-Ditetradecylacetamide (ALC-0159), etc. for PEGylated lipid nanoparticles for mRNA COVID-19 vaccine. We can offer custom GMP & Non-GMP grade PEG manufacturing services to meet customers’ different commercial development needs." said the Director of Production Department of Biopharma PEG.
As a reliable PEG supplier, Biopharma PEG can produce and provide below PEG products as ingredients used in COVID-19 vaccines. Please contact us at email@example.com immediately if you are interested in our PEG GMP manufacturing service or request additional information about our high quality GMP grade PEG products.
MF001002 - mPEG-OHBUY
MF001121 - mPEG-AA (mPEG-CM)BUY
MF001170 - mPEG-CH2CH2CH2-NH2BUY
MF001317 - mPEG-DMGBUY
MF001318 - mPEG-N,N-Ditetradecylacetamide (ALC-0159)
MF001096 - mPEG-DSPEBUY
MF001098 - mPEG-DPPEBUY
LP096005 - DSPE-PEG-NH2BUY
LP096072 - DSPE-PEG-GalactoseBUY
LP096282 - DSPE-PEG-Mannose
About Biopharma PEG
As a leading manufacturer of PEG derivatives, Biopharma PEG is fully competent and dedicated to serving mRNA vaccine companies with high purity PEG lipids. With comprehensive and advanced platforms, the company provides PEG derivatives and related products to customers worldwide to meet new drug delivery goals.
Biopharma PEG Scientific Inc.
Address: 108 Water Street, Room 4D, Watertown, MA 02472, USA